CompletedPhase 2ACTRN12609000702213

Study to compare the effects of taking 2.5mg of the antihstamine, Loratidine, four times a day with taking 10mg of Loratidine once a day in healthy volunteers

Maxiclear PD Study: A Double Blind, Randomised, Cross-over Trial to Compare the Pharmacodynamic Effects of Loratadine 2. 5 mg Four Times a Day with Loratadine 10 mg Once Daily in healthy volunteers.


Sponsor

AFT Pharmaceuticals Ltd

Enrollment

25 participants

Start Date

Sep 21, 2009

Study Type

Interventional

Conditions

Summary

Loratadine is usually given as a 10 mg dose once daily for the treatment of allergic condictions. However, based on pharmacokinetic principles it is likely that divided daily dosing such as 2.5 mg four times a day will also produce a similar effect on histamine effect compared with loratadine 10 mg once daily. This would enable smaller doses of loratadine to be combined with shorter acting agents such as phenylephrine.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 50 Yearss

Inclusion Criteria2

  • Healthy volunteers, males and females aged 18-50 years.
  • Females must be sterile or using adequate contraception.

Exclusion Criteria2

  • Participants who have any concomitant medications currently, or in the 7 days prior to the start of the each study phase. The only exception are oral contraceptives, ibuprofen and paracetamol.
  • Suffering from any other diseases or condition which, in the opinion of the investigator, means that it would not be in the participant's best interests to participate in this study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Loratadine 2.5 mg tablet four times a day orally for 72 hours. Participants who are on the this dose regimen in the first study phase will swap to the other dose regimen (loratadine 10 mg once daily)

Loratadine 2.5 mg tablet four times a day orally for 72 hours. Participants who are on the this dose regimen in the first study phase will swap to the other dose regimen (loratadine 10 mg once daily) in the second cross-over study phase. Washout is at least 10 days between these two study phases.


Locations(2)

Auckland, New Zealand

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000702213